Rachel P Ogilvie, J Bradley Layton, Patricia C Lloyd, Yixin Jiao, Djeneba Audrey Djibo, Hui Lee Wong, Joann F Gruber, Ron Parambi, Jie Deng, Michael Miller, Jennifer Song, Lisa B Weatherby, Lauren Peetluk, An-Chi Lo, Kathryn Matuska, Michael Wernecke, Christine L Bui, Tainya C Clarke, Sylvia Cho, Elizabeth J Bell, Grace Yang, Kandace L Amend, Richard A Forshee, Steven A Anderson, Cheryl N McMahill-Walraven, Yoganand Chillarige, Mary S Anthony, John D Seeger, Azadeh Shoaibi
BACKGROUND: COVID-19 vaccines are authorized for use in children in the United States; real-world assessment of vaccine effectiveness in children is needed. This study's objective was to estimate the effectiveness of receiving a complete primary series of monovalent BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine in US children. METHODS: This cohort study identified children aged 5-17 years vaccinated with BNT162b2 matched with unvaccinated children. Participants and BNT162b2 vaccinations were identified in Optum and CVS Health insurance administrative claims databases linked with Immunization Information System (IIS) COVID-19 vaccination records from 16 US jurisdictions between December 11, 2020, and May 31, 2022 (end date varied by database and IIS)...
April 26, 2024: BMC Pediatrics